Guideline of guidelines: non-muscle-invasive bladder cancer

Solomon L. Woldu, Aditya Bagrodia, Yair Lotan

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Non-muscle-invasive bladder cancer (NMIBC) represents the vast majority of bladder cancer diagnoses, but this definition represents a spectrum of disease with a variable clinical course, notable for significant risk of recurrence and potential for progression. Management involves risk-adapted strategies of cystoscopic surveillance and intravesical therapy with the goal of bladder preservation when safe to do so. Multiple organizational guidelines exist to help practitioners manage this complicated disease process, but adherence to management principles among practising urologists is reportedly low. We review four major organizational guidelines on NMIBC: the American Urological Association (AUA)/Society of Urologic Oncology (SUO), European Association of Urology (EAU), National Comprehensive Cancer Network (NCCN), and National Institute for Health and Care Excellence (NICE) guidelines.

Original languageEnglish (US)
Pages (from-to)371-380
Number of pages10
JournalBJU International
Volume119
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Urinary Bladder Neoplasms
Guidelines
National Institutes of Health (U.S.)
Risk Management
Urinary Bladder
Delivery of Health Care
Recurrence
Neoplasms
Therapeutics

Keywords

  • #BladderCancer
  • #blcsm
  • guidelines
  • management
  • non-muscle-invasive bladder cancer

ASJC Scopus subject areas

  • Urology

Cite this

Guideline of guidelines : non-muscle-invasive bladder cancer. / Woldu, Solomon L.; Bagrodia, Aditya; Lotan, Yair.

In: BJU International, Vol. 119, No. 3, 01.03.2017, p. 371-380.

Research output: Contribution to journalArticle

@article{a499fa01a2ce49bc9364776087070353,
title = "Guideline of guidelines: non-muscle-invasive bladder cancer",
abstract = "Non-muscle-invasive bladder cancer (NMIBC) represents the vast majority of bladder cancer diagnoses, but this definition represents a spectrum of disease with a variable clinical course, notable for significant risk of recurrence and potential for progression. Management involves risk-adapted strategies of cystoscopic surveillance and intravesical therapy with the goal of bladder preservation when safe to do so. Multiple organizational guidelines exist to help practitioners manage this complicated disease process, but adherence to management principles among practising urologists is reportedly low. We review four major organizational guidelines on NMIBC: the American Urological Association (AUA)/Society of Urologic Oncology (SUO), European Association of Urology (EAU), National Comprehensive Cancer Network (NCCN), and National Institute for Health and Care Excellence (NICE) guidelines.",
keywords = "#BladderCancer, #blcsm, guidelines, management, non-muscle-invasive bladder cancer",
author = "Woldu, {Solomon L.} and Aditya Bagrodia and Yair Lotan",
year = "2017",
month = "3",
day = "1",
doi = "10.1111/bju.13760",
language = "English (US)",
volume = "119",
pages = "371--380",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Guideline of guidelines

T2 - non-muscle-invasive bladder cancer

AU - Woldu, Solomon L.

AU - Bagrodia, Aditya

AU - Lotan, Yair

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Non-muscle-invasive bladder cancer (NMIBC) represents the vast majority of bladder cancer diagnoses, but this definition represents a spectrum of disease with a variable clinical course, notable for significant risk of recurrence and potential for progression. Management involves risk-adapted strategies of cystoscopic surveillance and intravesical therapy with the goal of bladder preservation when safe to do so. Multiple organizational guidelines exist to help practitioners manage this complicated disease process, but adherence to management principles among practising urologists is reportedly low. We review four major organizational guidelines on NMIBC: the American Urological Association (AUA)/Society of Urologic Oncology (SUO), European Association of Urology (EAU), National Comprehensive Cancer Network (NCCN), and National Institute for Health and Care Excellence (NICE) guidelines.

AB - Non-muscle-invasive bladder cancer (NMIBC) represents the vast majority of bladder cancer diagnoses, but this definition represents a spectrum of disease with a variable clinical course, notable for significant risk of recurrence and potential for progression. Management involves risk-adapted strategies of cystoscopic surveillance and intravesical therapy with the goal of bladder preservation when safe to do so. Multiple organizational guidelines exist to help practitioners manage this complicated disease process, but adherence to management principles among practising urologists is reportedly low. We review four major organizational guidelines on NMIBC: the American Urological Association (AUA)/Society of Urologic Oncology (SUO), European Association of Urology (EAU), National Comprehensive Cancer Network (NCCN), and National Institute for Health and Care Excellence (NICE) guidelines.

KW - #BladderCancer

KW - #blcsm

KW - guidelines

KW - management

KW - non-muscle-invasive bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=85012892798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012892798&partnerID=8YFLogxK

U2 - 10.1111/bju.13760

DO - 10.1111/bju.13760

M3 - Article

C2 - 28058776

AN - SCOPUS:85012892798

VL - 119

SP - 371

EP - 380

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 3

ER -